Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Extramedullary Relapse

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

Bone Marrow Transplantation volume 28, pages 1145–1150 (2001)Cite this article

Abstract

Treatment options for patients with myeloma who relapse after allogeneic stem cell transplantation are limited. Thalidomide, an antineoplastic agent, has been shown to be effective in multiple myeloma through proposed mechanisms that may include angiogenesis inhibition. Herein we report successful thalidomide treatment of four patients who relapsed following allogeneic transplantation, three of whom had predominantly extramedullary relapse. Thalidomide was well tolerated in all patients; in two patients interferon-α was subsequently added to thalidomide as maintenance therapy without worsening graft-versus-host disease. We suggest that extramedullary myeloma is particularly sensitive to thalidomide, speculating that growth biology may in part be dependent on angiogenesis.

Bone Marrow Transplantation (2001) 28, 1145–1150.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (see comments) New Engl J Med 1996 335: 91–97

    Article  CAS  Google Scholar 

  2. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections Br J Haematol 1996 93: 142–145

    Article  CAS  Google Scholar 

  3. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447–1456

    Article  CAS  Google Scholar 

  4. Mehta J, Tricot G, Jagannath S et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998 21: 887–892

    Article  CAS  Google Scholar 

  5. Mehta J, Singhal S . Graft-versus-myeloma Bone Marrow Transplant 1998 22: 835–843

    Article  CAS  Google Scholar 

  6. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 1996 88: 2787–2793

    CAS  PubMed  Google Scholar 

  7. Haslett PA, Corral LG, Albert M, Kaplan G . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med 1998 187: 1885–1892

    Article  CAS  Google Scholar 

  8. Kenyon BM, Browne F, D'Amato RJ . Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Exp Eye Res 1997 64: 971–978

    Article  CAS  Google Scholar 

  9. McHugh SM, Rifkin IR, Deighton J et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 1995 99: 160–167

    Article  CAS  Google Scholar 

  10. Gad SM, Shannon EJ, Krotoski WA, Hastings RC . Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males Lepr Rev 1985 56: 35–39

    CAS  PubMed  Google Scholar 

  11. Munshi N, Wilson C, Penn J et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies Blood 1998 92: (Suppl.) 98a (Abstr. 400)

    Google Scholar 

  12. Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma Br J Haematol 1994 87: 503–508

    Article  CAS  Google Scholar 

  13. Rajkumar SV, Fonseca R, Witzig TE et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma Leukemia 1999 13: 469–472

    Article  CAS  Google Scholar 

  14. Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 2000 96: 2943–2950

    CAS  PubMed  Google Scholar 

  15. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. (published erratum appears in New Engl J Med 2000 Feb 3;342(5):364) New Engl J Med 1999 341: 1565–1571

    Article  CAS  Google Scholar 

  16. Rajkumar SV, Fonseca R, Dispenzieri A et al. Thalidomide in the treatment of relapsed multiple myeloma Mayo Clin Proc 2000 75: 897–901

    Article  CAS  Google Scholar 

  17. Yakoub-Agha I, Moreau P, Leyvraz S et al. Thalidomide in patients with advanced myeloma Hematol J 2000 1: 186–189

    Article  CAS  Google Scholar 

  18. Zomas A, Anagnostopoulos N, Dimopoulos MA . Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent Bone Marrow Transplant 2000 25: 1319–1320

    Article  CAS  Google Scholar 

  19. Ludwig H, Fritz E, Zulian GB, Browman GP . Should-alpha-interferon be included as standard treatment in multiple myeloma? Eur J Cancer 1998 34: 12–24

    Article  CAS  Google Scholar 

  20. Morstyn G, Schechter GP, Ihde DC et al. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness Cancer Treat Rep 1984 68: 1439–1446

    CAS  PubMed  Google Scholar 

  21. Grigg A, Seymour JF, Roberts A, Szer J . Mini-allografts for haematological malignancies: an alternative to conventional myeloablative marrow transplantation Aust NZ J Med 1999 29: 308–314

    Article  CAS  Google Scholar 

  22. Weidner N, Semple JP, Welch WR, Folkman J . Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma New Engl J Med 1991 324: 1–8

    Article  CAS  Google Scholar 

  23. Vermeulen PB, Gasparini G, Fox SB et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation Eur J Cancer 1996 32A: 2474–2484

    Article  CAS  Google Scholar 

  24. Trullemans F, Schots R, Storme G, Camp BV . Late and localized extramedullary relapse of a light chain kappa myeloma after syngeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 115–117

    Article  CAS  Google Scholar 

  25. Zomas A, Stefanoudaki K, Fisfis M et al. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas Bone Marrow Transplant 1998 21: 1163–1165

    Article  CAS  Google Scholar 

  26. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect Leukemia 1997 11: 281–283

    Article  CAS  Google Scholar 

  27. Moreau P, Bataille R, Mahe B et al. High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma J Clin Oncol 1993 11: 1832

    Article  CAS  Google Scholar 

  28. Celsing F, Hast R, Stenke L et al. Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution? Eur J Haematol 1992 49: 108

    Article  CAS  Google Scholar 

  29. Chong G, Byrnes G, Szer J, Grigg A . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy Bone Marrow Transplant 2000 26: 1011–1015

    Article  CAS  Google Scholar 

  30. Rajkumar SV, Leong T, Roche PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 2000 6: 3111–3116

    CAS  PubMed  Google Scholar 

  31. Sanfructuoso C, Caballero MD, Garcia-Sanz R et al. Relapse of multiple myeloma in extramedullary sites after autologous bone marrow transplantation Eur J Haematol 1996 56: 181–183

    Article  CAS  Google Scholar 

  32. Lokhorst HM, Meuwissen OJ, Verdonck LF, Dekker AW . High-risk multiple myeloma treated with high-dose melphalan J Clin Oncol 1992 10: 47–51

    Article  CAS  Google Scholar 

  33. Lim SH, McWhannell A, Vora AJ, Boughton BJ . Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation Lancet 1988 1: 117

    Article  CAS  Google Scholar 

  34. Koc S, Leisenring W, Flowers ME et al. Thalidomide for treatment of patients with chronic graft-versus-host disease Blood 2000 96: 3995–3996

    CAS  PubMed  Google Scholar 

  35. Nagafuji K, Harada N, Eto T et al. Interferon-alpha treatment of acute lymphoblastic leukemia relapse after unrelated bone marrow transplantation Int J Hematol 1998 67: 63–68

    Article  CAS  Google Scholar 

  36. Steegmann JL, Casado LF, Tomas JF et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation Bone Marrow Transplant 1999 23: 483–488

    Article  CAS  Google Scholar 

  37. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome J Clin Oncol 2000 18: 3031–3037

    Article  CAS  Google Scholar 

  38. Mehta J, Singhal S . Graft-versus-myeloma Bone Marrow Transplant 1998 22: 835–843

    Article  CAS  Google Scholar 

  39. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation J Clin Oncol 1997 15: 433–444

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia

    JJ Biagi, L Mileshkin, DW Westerman & HM Prince

  2. Bone Marrow Transplant Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia

    AP Grigg

Authors
  1. JJ Biagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Mileshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. AP Grigg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. DW Westerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. HM Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biagi, J., Mileshkin, L., Grigg, A. et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 28, 1145–1150 (2001). https://doi.org/10.1038/sj.bmt.1703292

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703292

Keywords

This article is cited by

Search

Advanced search

Quick links